<DOC>
	<DOC>NCT01285453</DOC>
	<brief_summary>This study will assess the tolerability of combination therapy with ASA404 and docetaxel in Japanese patients with advanced or recurrent solid tumors.</brief_summary>
	<brief_title>Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vadimezan</mesh_term>
	<criteria>1. Patients with confirmed solid tumors whose disease has progressed or recurred after treatment at lease one therapy, except docetaxel 2. WHO Performance Status of 01 1. Patients having symptomatic CNS tumor/metastasis and requiring treatment 2. Patients who have received prior therapy with ASA404 or other vascular disrupting agents 3. Patients with systolic BP &gt; 160mmHg and/or diastolic BP &gt; 90mmHg 4. Patients with fluid retention 5. Patients with any one of cardiotoxicities 6. Concomitant use of drugs with a risk of prolonging the QT interval 7. Known allergy or hypersensitivity to taxane or polysorbate 80 Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>ASA404,</keyword>
	<keyword>vadimezan,</keyword>
	<keyword>docetaxel</keyword>
</DOC>